Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Temozolomide With or Without Hyperbaric Oxygen Therapy for Newly-Diagnosed Primary Glioblastoma
NCT07789379Phase 2Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2028
01
Overview
Phase 2, randomised, open-label trial of adebrelimab in glioblastoma (GBM) (2 arms). Primary endpoint: Progression-Free Survival at 24 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07789379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07789379.